BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22915026)

  • 21. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
    Yamazaki N; Maeda Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
    [No Abstract]   [Full Text] [Related]  

  • 22. Mutated ERBB4: a novel drug target in metastatic melanoma?
    Kurppa K; Elenius K
    Pigment Cell Melanoma Res; 2009 Dec; 22(6):708-10. PubMed ID: 19735458
    [No Abstract]   [Full Text] [Related]  

  • 23. Vascular endothelial growth factor receptors and the therapeutic targeting of angiogenesis in cancer: where do we go from here?
    Bruce D; Tan PH
    Cell Commun Adhes; 2011 Oct; 18(5):85-103. PubMed ID: 22017472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What can we learn from phase II adjuvant trials in melanoma?
    Keilholz U; Suciu S; Eggermont AM
    Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
    [No Abstract]   [Full Text] [Related]  

  • 27. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 28. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients.
    Meier F; Guenova E; Clasen S; Eigentler T; Forschner A; Leiter U; Zielinski C; Knaudt B; Garbe C; Berneburg M
    J Am Acad Dermatol; 2009 May; 60(5):863-8. PubMed ID: 19389529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
    Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
    Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
    Sato Y; Uhara H; Ashida A; Okuyama R
    J Dermatol; 2013 Dec; 40(12):1050-1. PubMed ID: 24330169
    [No Abstract]   [Full Text] [Related]  

  • 31. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
    Kunnakkat S; Mathew M; Narayana A
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
    Eisen T; Trefzer U; Hamilton A; Hersey P; Millward M; Knight RD; Jungnelius JU; Glaspy J
    Cancer; 2010 Jan; 116(1):146-54. PubMed ID: 19862820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Searching for the Achilles' heel of melanoma cells: new treatment modalities.
    Melnikova VO; Bar-Eli M
    Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130
    [No Abstract]   [Full Text] [Related]  

  • 35. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
    Mulders P
    BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
    Margolin KA
    Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
    [No Abstract]   [Full Text] [Related]  

  • 37. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 38. Emerging targeted therapies for breast cancer.
    Alvarez RH; Valero V; Hortobagyi GN
    J Clin Oncol; 2010 Jul; 28(20):3366-79. PubMed ID: 20530283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
    Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
    Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.